AGI-41998
Based on 1 Customer Validation
AGI-41998 is a potent and orally active inhibitor of methionine adenosyltransferase 2A (MAT2A) that effectively penetrates the blood-brain barrier. AGI-41998 exhibits inhibitory activities against MAT2A and S-adenosyl methionine (SAM) in HCT-116 MTAP-null cells with IC50s of 22 nM and 34 nM. AGI-41998 can significantly inhibit the proliferation of HCT-116 cells and tumor growth. AGI-41998 can be used to study the role of SAM regulation in the central nervous system (CNS) and colon cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.72%
- No. CAS: 2377492-26-5
- Fòrmula: C22H16BrF3N4O2
- Peso molecular:505.29
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Orally Active Compound Library
HY-L061
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Amino Acid Metabolism Compound Library
HY-L189
-
High-Throughput Bioactive Compound Library
HY-L205
Actividad biológica
AGI-41998 (4 days) inhibits HCT-116 MTAP-null and HCT-116 MTAPWT cell lines with GI50s of 66 nM and 1.65 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | CL | Vss | MRT | Cmax | AUC0-24 |
|---|---|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | p.o. | 0.354 L/h | 12.3 L/kg | 34.7 h | 4.90 μg/mL | 77.9 μg·h/mL |
AGI-41998 (30-60 mg/kg, p.o., once daily for 13 days) significantly inhibits tumor growth in KP4 xenograft mice models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human pancreatic ductal carcinoma (KP4) xenograft tumor model established in 5- to 6-week-old severe acquired immunodeficiency female Nu/Nu mice[1]
-
Dosage:30 and 60 mg/kg
-
Administration:Oral administration (p.o.), once daily for 13 days
-
Result:Significantly inhibited the growth of KP4 tumors at 60 mg/kg dose.
Decreased the SAM level in tumors by approximately 80%.
No significant weight loss.
Chemical Information
-
No. CAS 2377492-26-5
-
Appearance Solid
-
Peso molecular 505.29
-
Fòrmula C22H16BrF3N4O2
-
Color Light yellow to yellow
-
SMILES
O=C1C(C2=CC=C(Br)C=C2)=C3N=C(NCC(F)(F)F)N=CC3=CN1C4=CC=C(OC)C=C4
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 83.33 mg/mL (164.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9791 mL | 9.8953 mL | 19.7906 mL | 49.4765 mL |
| 5 mM | 0.3958 mL | 1.9791 mL | 3.9581 mL | 9.8953 mL | |
| 10 mM | 0.1979 mL | 0.9895 mL | 1.9791 mL | 4.9477 mL | |
| 15 mM | 0.1319 mL | 0.6597 mL | 1.3194 mL | 3.2984 mL | |
| 20 mM | 0.0990 mL | 0.4948 mL | 0.9895 mL | 2.4738 mL | |
| 25 mM | 0.0792 mL | 0.3958 mL | 0.7916 mL | 1.9791 mL | |
| 30 mM | 0.0660 mL | 0.3298 mL | 0.6597 mL | 1.6492 mL | |
| 40 mM | 0.0495 mL | 0.2474 mL | 0.4948 mL | 1.2369 mL | |
| 50 mM | 0.0396 mL | 0.1979 mL | 0.3958 mL | 0.9895 mL | |
| 60 mM | 0.0330 mL | 0.1649 mL | 0.3298 mL | 0.8246 mL | |
| 80 mM | 0.0247 mL | 0.1237 mL | 0.2474 mL | 0.6185 mL | |
| 100 mM | 0.0198 mL | 0.0990 mL | 0.1979 mL | 0.4948 mL |
Powered by Bioz